AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12368782 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion for 48 hours (placebo)
Number of subjects: 26
Study 10211628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-aminolevulinic acid (ALA) administration to normal volunteers
Number of subjects: 0
Study 10211628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-aminolevulinic acid (ALA) administration
Number of subjects: 0
Study 10211628 — intervention group
Group type: COMPARATOR
Intervention: Patients with ALAD deficiency porphyria and acute lead intoxication
Number of subjects: 0
Study 8585739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (5 days)
Number of subjects: 537
Study 8585739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (10 days)
Number of subjects: 537
Study 8585739 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (10 days)
Number of subjects: 537
Study 2715472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorethylenepropylene (Teflon) (FEP) with s.f.e. of 20 erg/cm2
Number of subjects: 12
Study 2715472 — intervention group
Group type: EXPERIMENTAL
Intervention: Parafilm (PAR) with s.f.e. of 26 erg/cm2
Number of subjects: 12
Study 2715472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose acetate (CA) with s.f.e. of 57 erg/cm2
Number of subjects: 12
Study 2715472 — intervention group
Group type: COMPARATOR
Intervention: Enamel (E) with s.f.e. of 88 erg/cm2
Number of subjects: 12
Study 64133 — intervention group
Group type: EXPERIMENTAL
Intervention: Celestin tube intubation
Number of subjects: 62
Study 64133 — intervention group
Group type: EXPERIMENTAL
Intervention: Procter-Livingstone tube intubation
Number of subjects: 62
Study 6123836 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg every 8 h for three days postoperatively)
Number of subjects: 90
Study 6123836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 8 h for three days postoperatively)
Number of subjects: 90
Study 31447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) + Abiraterone acetate and prednisolone (AAP)
Number of subjects: 901
Study 31447077 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 901
Study 28118996 — intervention group
Group type: EXPERIMENTAL
Intervention: Mel4 coated contact lenses
Number of subjects: 0
Study 27938405 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention with outreach visits (study group A - psychosocial rehabilitation)
Number of subjects: 14847
Study 27938405 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention with outreach visits (study group B - physical rehabilitation)
Number of subjects: 14847
Study 27938405 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention
Number of subjects: 14847
Study 23895201 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated school-parent-worksite program that targeted healthy home food environments and energy balance self-monitoring
Number of subjects: 38
Study 23895201 — intervention group
Group type: COMPARATOR
Intervention: Identical school-based program without worksite support
Number of subjects: 38
Study 22761074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 7
Study 22761074 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 7
Study 19331702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic-containing starter formula supplemented with Lactobacillus paracasei ssp. paracasei and Bifidobacterium animalis ssp. lactis
Number of subjects: 126
Study 19331702 — intervention group
Group type: COMPARATOR
Intervention: Control group (same formula without probiotics)
Number of subjects: 126
Study 17606474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary 5-HT stimulation (tryptophan-rich alpha-lactalbumin, 4.8 g/100 g TRP)
Number of subjects: 37
Study 17606474 — intervention group
Group type: COMPARATOR
Intervention: Placebo protein (1.4 g/100 g TRP)
Number of subjects: 37
Study 15337807 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (group sessions, one session per week for 4 months)
Number of subjects: 227
Study 15337807 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 227
Study 12215311 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen
Number of subjects: 0
Study 12215311 — intervention group
Group type: COMPARATOR
Intervention: Estrogen therapy
Number of subjects: 0
Study 12215311 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy
Number of subjects: 0
Study 9844983 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents with autism
Number of subjects: 0
Study 9844983 — intervention group
Group type: COMPARATOR
Intervention: Nonautistic mentally retarded individuals
Number of subjects: 0
Study 7744517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane membrane
Number of subjects: 87
Study 7744517 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylonitril membrane
Number of subjects: 87
Study 2735740 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 12
Study 2735740 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 12
Study 2735740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (24-day course)
Number of subjects: 1
Study 2098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (16-day course)
Number of subjects: 1
Study 2098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 1
Study 2098 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 1
Study 2098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 30997784 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 40
Study 30997784 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 40
Study 28931220 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimens
Number of subjects: 1833
Study 25728808 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) via colonoscopy
Number of subjects: 20
Study 25728808 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times a day for 3 days, followed by 125-500 mg/day every 2-3 days for at least 3 weeks)
Number of subjects: 20
Study 23380105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valproic acid (iVPA) 400 mg
Number of subjects: 60
Study 23380105 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular metoclopramide + subcutaneous sumatriptan (10 mg + 6 mg)
Number of subjects: 60
Study 20880552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 7353
Study 20880552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7353
Study 19391535 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture, moving cupping, blood‐letting puncture
Number of subjects: 176
Study 19391535 — intervention group
Group type: COMPARATOR
Intervention: Medication (oral administration of Vit E and Vit C)
Number of subjects: 176
Study 16805717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic treatments (e.g., thiazolidinediones)
Number of subjects: 0
Study 14702242 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 111
Study 14702242 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 111
Study 14702242 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 111
Study 14702242 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 111
Study 10776514 — intervention group
Group type: COMPARATOR
Intervention: Humoral immunity assessment using SRID method for IgG, IgM, and IgA levels.
Number of subjects: 0
Study 10776514 — intervention group
Group type: COMPARATOR
Intervention: Cell mediated immunity assessment measuring total T cells, Th cells, Ts cells, and Th:Ts cell ratio.
Number of subjects: 0
Study 8801162 — intervention group
Group type: EXPERIMENTAL
Intervention: N-(4-hydroxyphenyl) retinamide (4HPR)
Number of subjects: 0
Study 8801162 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoyl β-glucuronide (RAG)
Number of subjects: 0
Study 1642910 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal field block with lignocaine before operation
Number of subjects: 32
Study 1642910 — intervention group
Group type: COMPARATOR
Intervention: Inguinal field block with lignocaine after operation
Number of subjects: 32
Study 6383741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide (100 mg twice daily or three times daily)
Number of subjects: 26
Study 6383741 — intervention group
Group type: COMPARATOR
Intervention: Quinidine gluconate (324 mg three times daily)
Number of subjects: 26
Study 6383741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 26
Study 6383741 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 26
Study 30040032 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized corrective exercises performed 3 times per week for 4 weeks
Number of subjects: 44
Study 30040032 — intervention group
Group type: COMPARATOR
Intervention: Standard warm-up drills as part of morning physical training
Number of subjects: 44
Study 29575941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab monthly for 12 months
Number of subjects: 36
Study 29575941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab monthly for 4 months followed by pro re nata injections
Number of subjects: 36
Study 29575941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab monthly for 12 months
Number of subjects: 36
Study 29575941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab monthly for 4 months followed by pro re nata injections
Number of subjects: 36
Study 29575941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ranibizumab
Number of subjects: 36
Study 29575941 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose ranibizumab
Number of subjects: 36
Study 29575941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (vascularized serous pigment epithelial detachment)
Number of subjects: 36
Study 29575941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (fibrovascular pigment epithelial detachment)
Number of subjects: 36
Study 27245056 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 49
Study 27245056 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 49
Study 24477817 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 24477817 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 0
Study 24477817 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol plus NAC
Number of subjects: 0
Study 24188942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck flexion with lateral pressure
Number of subjects: 150
Study 24188942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting of the larynx
Number of subjects: 150
Study 24188942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 19834507 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cyclosporine A (CsA) and artificial tear-drop treatment
Number of subjects: 42
Study 19834507 — intervention group
Group type: COMPARATOR
Intervention: Topical artificial tear-drop treatment
Number of subjects: 42
Study 18277888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanaro uncovered metal stent
Number of subjects: 92
Study 18277888 — intervention group
Group type: COMPARATOR
Intervention: Luminex uncovered metal stent
Number of subjects: 92
Study 15764758 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent RV pacing
Number of subjects: 17
Study 15764758 — intervention group
Group type: COMPARATOR
Intervention: Back-up pacing
Number of subjects: 17
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg IM or IV within 72 hours of delivery
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg IM or IV within 72 hours of delivery
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg at 28 weeks' gestation
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg at 28 weeks and 34 weeks
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after miscarriage or abortion after 12 weeks' gestation
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg before 12 weeks' gestation after miscarriage or abortion
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after ectopic pregnancy
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after chorionic villous sampling
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after cordocentesis
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg or 300 microg for quantitating FMH
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for FMH after events associated with placental trauma
Number of subjects: 0
Study 12970812 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal or written informed consent prior to administration of Rh immune globulin
Number of subjects: 0
Study 11077903 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (PSA, DRE, TRUS, biopsy on indication)
Number of subjects: 626
Study 11077903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 626
Study 11077903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (refusers vs attenders)
Number of subjects: 626
Study 8898425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/hepatitis B vaccine
Number of subjects: 156
Study 1893686 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI/MI (100 ppm)
Number of subjects: 4713
Study 1893686 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI/MI-preserved product
Number of subjects: 4713
Study 1893686 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 4713
Study 1893686 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting of MCI/MI sensitized patients
Number of subjects: 4713
Study 6402951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen flow of 8 litres/minute delivered via Magill or Bain breathing attachment
Number of subjects: 32
Study 6402951 — intervention group
Group type: EXPERIMENTAL
Intervention: Magill breathing system with reservoir bag filled with oxygen prior to application
Number of subjects: 32
Study 6402951 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-tight fits of face masks on patients
Number of subjects: 32
Study 31952280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and lactose hydrate (placebo of MgO)
Number of subjects: 60
Study 31952280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and Magnesium Oxide (MgO)
Number of subjects: 60
Study 31952280 — intervention group
Group type: COMPARATOR
Intervention: Placebo of Lactobacillus reuteri DSM 17938 and Magnesium Oxide (MgO)
Number of subjects: 60
Study 30995673 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at +5 cm H2O
Number of subjects: 49
Study 30995673 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 49
Study 28298878 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) oxygen therapy
Number of subjects: 110
Study 28298878 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COG)
Number of subjects: 110
Study 27765582 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA Dose I ‐ 1 g bolus followed by 1 g infusion over 8 h
Number of subjects: 18
Study 27765582 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA Dose II ‐ 1 g bolus followed by 10 mg/kg/hr until the end of surgery
Number of subjects: 18
Study 27765582 — intervention group
Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 18
Study 24311515 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g EPA-rich lipid for 12 weeks
Number of subjects: 79
Study 24311515 — intervention group
Group type: COMPARATOR
Intervention: Control lipid for 12 weeks
Number of subjects: 79
Study 24311515 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA supplementation
Number of subjects: 79
Study 22203134 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) group
Number of subjects: 31
Study 22203134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 19370408 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and past sexual behavior as precursors
Number of subjects: 0
Study 19370408 — intervention group
Group type: COMPARATOR
Intervention: Control variables (age and past behavior)
Number of subjects: 0
Study 18589448 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (n = 76)
Number of subjects: 175
Study 18589448 — intervention group
Group type: COMPARATOR
Intervention: NPH/Lente (n = 81)
Number of subjects: 175
Study 18589448 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 175
Study 18589448 — intervention group
Group type: COMPARATOR
Intervention: NPH/Lente
Number of subjects: 175
Study 15800958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving resection
Number of subjects: 130
Study 15800958 — intervention group
Group type: COMPARATOR
Intervention: Standard Whipple operation
Number of subjects: 130
Study 15800958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 130
Study 12357140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 8
Study 12357140 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 8
Study 10491451 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fluticasone propionate (2000 microg/day, FP2000)
Number of subjects: 120
Study 10491451 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (30 mg/day)
Number of subjects: 120
Study 10491451 — intervention group
Group type: COMPARATOR
Intervention: Lower dose fluticasone propionate (500 microg/day, FP500)
Number of subjects: 120
Study 8367920 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg s.c. once every four weeks) and flutamide (250 mg three times daily)
Number of subjects: 327
Study 8367920 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 327
Study 2425334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation
Number of subjects: 0
Study 31578169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg daily
Number of subjects: 253
Study 31578169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 29411272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 2149
Study 29411272 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2149
Study 26810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sciatic block (boluses on demand only)
Number of subjects: 140
Study 26810904 — intervention group
Group type: COMPARATOR
Intervention: Continuous sciatic block (continuous infusion)
Number of subjects: 140
Study 26810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intermittent and Continuous)
Number of subjects: 140
Study 25363150 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 64
Study 25363150 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments including rituximab
Number of subjects: 64
Study 23754611 — intervention group
Group type: COMPARATOR
Intervention: Control transurethral resection of the bladder (TURB) with standardized tumor documentation
Number of subjects: 167
Study 21403017 — intervention group
Group type: COMPARATOR
Intervention: Placebo group of the DATATOP trial
Number of subjects: 157
Study 19595163 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal activity in the ventrolateral thalamus (Vop/Vim) in ET patients
Number of subjects: 20
Study 19595163 — intervention group
Group type: COMPARATOR
Intervention: Neuronal activity in the ventrolateral thalamus (Vop/Vim) in PD patients
Number of subjects: 20
Study 19595163 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MSFR levels in Vop/Vim between ET and PD patients
Number of subjects: 20
Study 16494147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg
Number of subjects: 44
Study 16494147 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control group)
Number of subjects: 44
Study 15100716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet (HFD) with Nib meal frequency
Number of subjects: 10
Study 15100716 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre diet (LFD) with Nib meal frequency
Number of subjects: 10
Study 15100716 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre diet (LFD)
Number of subjects: 10
Study 15100716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet (HFD)
Number of subjects: 10
Study 10934908 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition memory task using 'remember' (R) and 'know' (K) judgments
Number of subjects: 0
Study 10934908 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis of positive waveform elicited by test list words
Number of subjects: 0
Study 9612877 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67
Study 9612877 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 67
Study 9612877 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 8071050 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 190
Study 8071050 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 190